Abstract Despite advances in immunotherapy, unresectable stage III non-small-cell lung cancer (NSCLC) remains a highly challenging disease, with only around one-third of patients remaining disease-free at 5 years. The PACIFIC trial established consolidation with the anti-PD-L1 antibody durvalumab after concurrent chemoradiotherapy as the standard-of-care approach.
Antonin Levy
As seen in:
Nature,
JAMA Oncology,
Cell Press,
The Lancet,
Lexology,
Future Medicine,
European Journal of Cancer,
Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Antonin
Contact Antonin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack